Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus CCFM1138 is a specific strain of the probiotic bacterium *Lactobacillus rhamnosus*. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. *Lactobacillus rhamnosus* strains are commonly found in the human gastrointestinal tract and are known for their ability to survive in acidic and basic conditions, adhere to intestinal walls, and colonize the gut. They exert their beneficial effects primarily by modulating the gut microbiota, inhibiting the growth of pathogenic bacteria through the production of antimicrobial substances, and enhancing the body's immune response both locally in the gut and systemically. Additionally, they contribute to maintaining gut barrier integrity and producing short-chain fatty acids (SCFAs) that nourish colon cells. While specific detailed mechanisms and clinical data for the CCFM1138 strain are limited in publicly available information, *Lactobacillus rhamnosus* in general is associated with benefits such as improving digestive health, alleviating certain types of diarrhea, and modulating immune function. This specific strain is patented by Hubei Junyao Health Drink Co., Ltd..
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus rhamnosus CCFM1138.